Advanced HCC: 2nd line treatment selection and the right time to switch

COR2ED Medical Education

Treść dostarczona przez COR2ED. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez COR2ED lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.

1y ago 29:25

MP3•Źródło odcinka

COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leuven, Belgium, discuss the new era in treating patients with advanced HCC, focusing on treatment selection and the right time to switch to 2^nd line therapy.

In this podcast, the experts give an overview of the current 1^st and 2^nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2^nd line systemic therapies between Europe and USA.

The experts present their approach in making the decision to switch to 2^nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2^nd line therapy.

89 odcinków

#Science #COR2ED #Higher Education #Medical Education #Fitness #Podcasting Education #Medicine